{"nctId":"NCT00489970","briefTitle":"Persistence Study of GSK Biologicals' Tdap Vaccine 1, 3, 5 and 9 Years Following Administration as an Initial Single Dose in Healthy Young Adults and to Evaluate the Immunogenicity and Safety of Boostrix as a Second Dose of Tdap, When Administered at Year 9","startDateStruct":{"date":"2007-06-01","type":"ACTUAL"},"conditions":["Acellular Pertussis","Tetanus","Diphtheria"],"count":1954,"armGroups":[{"label":"Boostrix Group","type":"EXPERIMENTAL","interventionNames":["Procedure: Taking of blood samples","Biological: Boostrix"]},{"label":"Adacel Group","type":"ACTIVE_COMPARATOR","interventionNames":["Procedure: Taking of blood samples","Biological: Boostrix","Biological: Adacel"]},{"label":"Control group","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: Boostrix"]}],"interventions":[{"name":"Taking of blood samples","otherNames":[]},{"name":"Boostrix","otherNames":[]},{"name":"Adacel","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n• Persistence follow-up phase up to Year 9 time point:\n\nThe following criteria are applicable to subjects who refuse vaccination at Year 8 time point:\n\nAll subjects who received study vaccination (Boostrix or Adacel) in study NCT00346073 will be considered eligible to participate in this study.\n\nWritten informed consent must be obtained from the subject prior to each study time point.\n\nVaccination phase at Year 9 applicable for subjects in Boostrix and Adacel groups only:\n\nThe following criterion is applicable to subjects willing to consent to vaccination at Year 9 time point in the Boostrix and Adacel groups:\n\n• All subjects who received study vaccination (Boostrix or Adacel) in study NCT00346073 will be considered eligible to participate in this study.\n\nVaccination phase at Year 9 applicable for subjects in the Control group only:\n\nThe following criterion is applicable to subjects willing to consent to vaccination at Year 9 time point in the Control group only:\n\n• Subjects within the age range of 28-73 years will be considered eligible to participate in this study in the Control group.\n\nVaccination phase at Year 9 applicable for ALL subjects (Control, Boostrix and Adacel groups):\n\nThe following criteria are applicable to subjects willing to consent to vaccination at Year 9 time point in the Boostrix, Adacel and Control groups:\n\nAll subjects must satisfy the following criteria at study entry at Year 9 time point:\n\nSubjects who, in the opinion of the investigator, can and will comply with the requirements of the protocol (e.g. completion of the diary cards, return for follow-up visits).\n\nWritten informed consent obtained from the subject for vaccination at Year 9 time point.\n\nHealthy subjects as established by medical history and clinical examination before entering into the study.\n\n* Female subjects of non-childbearing potential may be enrolled in the study.\n\n  * Non-childbearing potential is defined as pre-menarche, current tubal ligation, hysterectomy, ovariectomy or post-menopause.\n* Female subjects of child bearing potential may be enrolled in the study, if the subject\n\n  * has practiced adequate contraception for 30 days prior to vaccination, and\n  * has a negative pregnancy test on the day of vaccination, and\n  * has agreed to continue adequate contraception for 1 month after completion of the vaccine dose\n\nExclusion Criteria:\n\nThe following criteria should be checked at the time of Year 9 vaccination time point. If any criteria is applicable, the subject must not be vaccinated in the study:\n\nFor subjects in Boostrix and Adacel groups:\n\n• Administration of Tdap vaccine since the last dose received in the study NCT00346073.\n\nFor subjects in the Control group:\n\n• Administration of Tdap (Boostrix or Adacel) vaccine at any time prior to the administration of Boostrix vaccine in this study.\n\nFor ALL subjects (Control, Boostrix and Adacel groups):\n\nUse of any investigational or non-registered product other than the study vaccine within 30 days preceding the dose of study vaccine, or planned use during the study period, 31 days (Day 0-30).\n\n* Chronic administration (defined as more than 14 days in total) of immunosuppressants or other immune-modifying drugs within six months prior to Visit 6 (pre-vacc). Inhaled and topical steroids are allowed.\n* Planned administration/administration of a vaccine not foreseen by the study protocol in the period starting 30 days before and ending 30 days after the dose of vaccine, with the exception of inactivated Influenza vaccine which is allowed throughout the study period, 31 days (Day 0-30).\n\n  \\-- Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational vaccine/product.\n* Hypersensitivity to latex.\n* History of diphtheria, tetanus or pertussis diseases.\n* Severe allergic reaction (e.g. anaphylaxis) after previous administration of any tetanus toxoid, diphtheria toxoid, or pertussis-antigen containing vaccines, or any component of Boostrix.\n* History of any neurological disorders or seizures.\n* Encephalopathy (e.g. coma, decreased level of consciousness, prolonged seizures) of unknown etiology occurring within seven days following previous vaccination with pertussis-containing vaccine.\n* Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination (no laboratory testing required).\n* Acute disease and/or fever at the time of enrolment.\n\n  * Fever is defined as temperature ≥ 100.4°F by any route. The preferred route for recording temperature in this study will be oral.\n  * Subjects with a minor illness (such as mild diarrhea, mild upper respiratory infection) without fever may, be enrolled at the discretion of the investigator.\n* Administration of immunoglobulins and/or any blood products within three months preceding the dose of study vaccine or planned administration during the study period, 31 days (Day 0-30).\n\nAdministration of any tetanus or diphtheria containing vaccine or any registered or investigational vaccine utilizing a diphtheria toxoid or tetanus toxoid carrier within 5 years prior to the administration of Boostrix vaccine in this study.\n\n* Acute or chronic, clinically significant pulmonary, cardiovascular, hepatic or renal functional abnormality, as determined by physical examination or laboratory screening tests.\n* Pregnant or lactating female.\n* Female planning to become pregnant or planning to discontinue contraceptive precautions during the 31 day (Day 0-30) follow-up period post-vaccination.","healthyVolunteers":true,"sex":"ALL","minimumAge":"28 Years","maximumAge":"73 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Subjects With Anti-diphtheria (Anti-D) Antibody Concentrations Greater Than or Equal to (≥) Protocol Specified Cut-off","description":"Anti-D cut-off was defined as ≥ 0.1 International Units per milliliter (IU/mL) determined with Enzyme-linked Immunosorbent Assay (ELISA)","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"967","spread":null},{"groupId":"OG001","value":"489","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Subjects With Anti-D Antibody Concentrations ≥ Protocol Specified Cut-off","description":"Anti-D cut-off was defined as ≥ 0.1 IU/mL as assessed by ELISA","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"857","spread":null},{"groupId":"OG001","value":"425","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Subjects With Anti-D Antibody Concentrations ≥ Protocol Specified Cut-off","description":"Anti-D cut-off was defined as ≥ 0.1IU/mL as assessed by ELISA.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"735","spread":null},{"groupId":"OG001","value":"359","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Subjects With Anti-D Antibody Concentrations ≥ Protocol Specified Cut-off","description":"Anti-D cut-off was defined as ≥ to 0.1IU/mL as assessed by ELISA.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"245","spread":null},{"groupId":"OG001","value":"113","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Subjects With Anti-tetanus (Anti-T) Antibody Concentrations ≥ Protocol Specified Cut-off","description":"Anti-T cut-off was defined as ≥ 0.1 IU/mL as assessed by ELISA.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1000","spread":null},{"groupId":"OG001","value":"504","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Subjects With Anti-T Antibody Concentrations ≥ Protocol Specified Cut-off","description":"Anti-T cut-off was defined as ≥ 0.1 IU/mL as assessed by ELISA.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"899","spread":null},{"groupId":"OG001","value":"440","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Subjects With Anti-T Antibody Concentrations ≥ Protocol Specified Cut-off","description":"Anti-T cut-off was defined as ≥ 0.1 IU/mL as assessed by ELISA.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"772","spread":null},{"groupId":"OG001","value":"370","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Subjects With Anti-T Antibody Concentrations ≥ Protocol Specified Cut-off","description":"Anti-T cut-off was defined as ≥ 0.1 IU/mL as assessed by ELISA.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"263","spread":null},{"groupId":"OG001","value":"120","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Subjects With Anti-D and Anti-T Concentrations ≥ 0.1 IU/mL and 1 IU/mL","description":"Number of subjects with anti-D and anti-T concentrations ≥ 0.1 IU/mL and 1 IU/mL were tabulated","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"245","spread":null},{"groupId":"OG001","value":"113","spread":null},{"groupId":"OG002","value":"265","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"263","spread":null},{"groupId":"OG001","value":"120","spread":null},{"groupId":"OG002","value":"304","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"114","spread":null},{"groupId":"OG001","value":"54","spread":null},{"groupId":"OG002","value":"92","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"211","spread":null},{"groupId":"OG001","value":"101","spread":null},{"groupId":"OG002","value":"231","spread":null}]}]}]},{"type":"PRIMARY","title":"Anti-pertussis Toxoid (Anti-PT), Anti-filamentous Hemagglutinin (Anti-FHA) and Anti-pertactin (Anti-PRN) Antibody Concentrations","description":"Anti-PT, anti-FHA and anti-PRN antibody concentrations were measured by ELISA, tabulated as GMCs and expressed in IU/mL.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.2","spread":null},{"groupId":"OG001","value":"7.8","spread":null},{"groupId":"OG002","value":"5.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"42.2","spread":null},{"groupId":"OG001","value":"28.4","spread":null},{"groupId":"OG002","value":"23.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"63.8","spread":null},{"groupId":"OG001","value":"64.7","spread":null},{"groupId":"OG002","value":"17.8","spread":null}]}]}]},{"type":"PRIMARY","title":"Anti-pertussis Toxoid (Anti-PT), Anti-filamentous Hemagglutinin (Anti-FHA) and Anti-pertactin (Anti-PRN) Antibody Concentrations","description":"Anti-PT, anti-FHA and anti-PRN antibody concentrations were measured by ELISA, tabulated as GMCs and expressed in IU/mL.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"64.1","spread":null},{"groupId":"OG001","value":"70.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"247.9","spread":null},{"groupId":"OG001","value":"254.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"405.4","spread":null},{"groupId":"OG001","value":"511.8","spread":null}]}]}]},{"type":"PRIMARY","title":"Booster Response to D and T Antigens","description":"A booster response was defined as: for initially seronegative subjects (S-) (pre-vaccination concentration below cut-off: \\< 0.1 IU/mL) antibody concentrations at least four times the cut-off (post vaccination concentration ≥ 0.4 IU/mL); for initially seropositive subjects (S+) (pre-vaccination concentration ≥ 0.1 IU/mL): an increase in antibody concentrations of at least four times the pre-vaccination concentration; Total = subjects either seropositive or seronegative.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16","spread":null},{"groupId":"OG001","value":"3","spread":null},{"groupId":"OG002","value":"35","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"153","spread":null},{"groupId":"OG001","value":"68","spread":null},{"groupId":"OG002","value":"187","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"169","spread":null},{"groupId":"OG001","value":"71","spread":null},{"groupId":"OG002","value":"222","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG002","value":"18","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"121","spread":null},{"groupId":"OG001","value":"44","spread":null},{"groupId":"OG002","value":"139","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"126","spread":null},{"groupId":"OG001","value":"44","spread":null},{"groupId":"OG002","value":"157","spread":null}]}]}]},{"type":"PRIMARY","title":"Booster Response to PT, FHA and PRN Antigens","description":"Booster response was defined as: for subjects with pre-vaccination antibody concentration \\< 5 EL.U/mL (S-): antibody concentration ≥ 20 EL.U/mL; for subjects with pre-vaccination antibody concentration ≥ 5 EL.U/mL and \\< 20 EL.U/mL (S+, \\<4\\*cut-off): antibody concentration at least four times the pre-vaccination concentration; for subjects with pre-vaccination antibody concentration ≥ 20 EL.U/mL (S+, ≥4\\*cut-off): antibody concentration at least two times the pre-vaccination concentration; Total = subjects either seropositive or seronegative","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"34","spread":null},{"groupId":"OG001","value":"10","spread":null},{"groupId":"OG002","value":"101","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"106","spread":null},{"groupId":"OG001","value":"53","spread":null},{"groupId":"OG002","value":"94","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"95","spread":null},{"groupId":"OG001","value":"43","spread":null},{"groupId":"OG002","value":"97","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"235","spread":null},{"groupId":"OG001","value":"106","spread":null},{"groupId":"OG002","value":"292","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16","spread":null},{"groupId":"OG001","value":"9","spread":null},{"groupId":"OG002","value":"70","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"216","spread":null},{"groupId":"OG001","value":"106","spread":null},{"groupId":"OG002","value":"228","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"232","spread":null},{"groupId":"OG001","value":"116","spread":null},{"groupId":"OG002","value":"303","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"31","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"27","spread":null},{"groupId":"OG001","value":"10","spread":null},{"groupId":"OG002","value":"75","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"179","spread":null},{"groupId":"OG001","value":"87","spread":null},{"groupId":"OG002","value":"175","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"210","spread":null},{"groupId":"OG001","value":"98","spread":null},{"groupId":"OG002","value":"281","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Anti-pertussis Toxoid (PT) Antibody Concentrations Equal to or Above Protocol Specified Cut-off","description":"The cut-off for anti-PT concentrations was defined as ≥ 5 ELISA units per mililiter (EL.U/mL).","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"917","spread":null},{"groupId":"OG001","value":"435","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"751","spread":null},{"groupId":"OG001","value":"316","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"670","spread":null},{"groupId":"OG001","value":"285","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Anti-PT Antibody Concentrations Equal to or Above Protocol Specified Cut-off","description":"The cut-off for anti-PT concentrations was defined as equal to or greater than 2.693 IU/mL.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"230","spread":null},{"groupId":"OG001","value":"106","spread":null},{"groupId":"OG002","value":"209","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"268","spread":null},{"groupId":"OG001","value":"120","spread":null},{"groupId":"OG002","value":"322","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Anti-FHA Antibody Concentrations Equal to or Above Protocol Specified Cut-off","description":"The cut-off for anti-FHA concentrations was defined as equal to or greater than 5 EL.U/mL.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1012","spread":null},{"groupId":"OG001","value":"501","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"913","spread":null},{"groupId":"OG001","value":"437","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"788","spread":null},{"groupId":"OG001","value":"368","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Anti-FHA Antibody Concentrations Equal to or Above Protocol Specified Cut-off","description":"The cut-off for anti-FHA concentrations was defined as equal to or greater than 2.046 IU/mL","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"271","spread":null},{"groupId":"OG001","value":"119","spread":null},{"groupId":"OG002","value":"322","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"271","spread":null},{"groupId":"OG001","value":"121","spread":null},{"groupId":"OG002","value":"327","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Anti-PRN Antibody Concentrations Equal to or Above Protocol Specified Cut-off","description":"The cut-off for anti-PRN concentrations was defined as equal to or greater than 5 EL.U/mL.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"971","spread":null},{"groupId":"OG001","value":"489","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"862","spread":null},{"groupId":"OG001","value":"426","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"755","spread":null},{"groupId":"OG001","value":"362","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Anti-PRN Antibody Concentrations Equal to or Above Protocol Specified Cut-off","description":"The cut-off for anti-PRN concentrations was defined as equal to or greater than 2.187 IU/mL.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"267","spread":null},{"groupId":"OG001","value":"117","spread":null},{"groupId":"OG002","value":"284","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"271","spread":null},{"groupId":"OG001","value":"121","spread":null},{"groupId":"OG002","value":"326","spread":null}]}]}]},{"type":"SECONDARY","title":"Anti-D Antibody Concentration","description":"Anti-D antibody concentration is expressed as geometric mean concentration (GMC) in IU/mL.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.4","spread":null},{"groupId":"OG001","value":"1.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.9","spread":null},{"groupId":"OG001","value":"1.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.8","spread":null},{"groupId":"OG001","value":"0.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Anti-D Antibody Concentration","description":"Anti-D antibody concentration is expressed as GMC in IU/mL.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.7","spread":null},{"groupId":"OG001","value":"0.8","spread":null},{"groupId":"OG002","value":"0.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.1","spread":null},{"groupId":"OG001","value":"4.7","spread":null},{"groupId":"OG002","value":"4.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Anti-T Antibody Concentration","description":"Anti-T antibody concentration is expressed as GMC in IU/mL.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.4","spread":null},{"groupId":"OG001","value":"4.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.2","spread":null},{"groupId":"OG001","value":"2.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.0","spread":null},{"groupId":"OG001","value":"2.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Anti-T Antibody Concentration","description":"Anti-T antibody concentration is expressed as GMC in IU/mL.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.8","spread":null},{"groupId":"OG001","value":"2.3","spread":null},{"groupId":"OG002","value":"1.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.4","spread":null},{"groupId":"OG001","value":"8.6","spread":null},{"groupId":"OG002","value":"8.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Anti-PT Antibody Concentration","description":"Anti-PT antibody concentration is expressed as GMC in EL.U/mL.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22.4","spread":null},{"groupId":"OG001","value":"15.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14.1","spread":null},{"groupId":"OG001","value":"10.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14.6","spread":null},{"groupId":"OG001","value":"11.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Anti-PT Antibody Concentration","description":"Anti-PT antibody concentration was expressed as GMC in IU/mL.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.2","spread":null},{"groupId":"OG001","value":"7.8","spread":null},{"groupId":"OG002","value":"5.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"64.1","spread":null},{"groupId":"OG001","value":"70.4","spread":null},{"groupId":"OG002","value":"66.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Anti-FHA Antibody Concentration","description":"Anti-FHA antibody concentration is expressed as GMC in IU/mL","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"190.1","spread":null},{"groupId":"OG001","value":"118.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"114.1","spread":null},{"groupId":"OG001","value":"81.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"110.0","spread":null},{"groupId":"OG001","value":"80.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Anti-FHA Antibody Concentration","description":"Anti-FHA antibody concentration was expressed as GMC in IU/mL.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"42.2","spread":null},{"groupId":"OG001","value":"28.4","spread":null},{"groupId":"OG002","value":"23.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"247.9","spread":null},{"groupId":"OG001","value":"254.6","spread":null},{"groupId":"OG002","value":"373.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Anti-PRN Antibody Concentration","description":"Anti-PRN antibody concentration is expressed as GMC in IU/mL","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"152.2","spread":null},{"groupId":"OG001","value":"132.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"82.5","spread":null},{"groupId":"OG001","value":"70.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"85.3","spread":null},{"groupId":"OG001","value":"77.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Anti-PRN Antibody Concentration","description":"Anti-PRN antibody concentration is expressed as GMC in IU/mL.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"63.8","spread":null},{"groupId":"OG001","value":"64.7","spread":null},{"groupId":"OG002","value":"17.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"405.4","spread":null},{"groupId":"OG001","value":"511.8","spread":null},{"groupId":"OG002","value":"336.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Alternative Booster Response to Anti-D and Anti-T Antigens","description":"Alternative Booster response to D and T antigens is defined as: - For subjects with pre-booster antibody concentration below 0.1 IU/mL: antibody concentrations at least four times the 0.1IU/ML, one month after vaccination, and - For subjects with pre-booster antibody concentration ≥0.1 IU/mL and \\<1.0 IU/mL: antibody concentrations of at least four times the pre-booster antibody concentration, one month after vaccination. - For subjects with pre-booster antibody concentration ≥1.0 IU/mL and \\<6.0 IU/mL: antibody concentrations of at least two times the pre-booster antibody concentration, one month after vaccination. - Subjects with pre-booster antibody concentration ≥6.0 IU/mL are not evaluable for booster response. S- = Antibody concentration \\< 0.1 IU/mL S+ = Antibody concentration ≥ 0.1 IU/mL Total = subjects either seropositive or seronegative","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16","spread":null},{"groupId":"OG001","value":"3","spread":null},{"groupId":"OG002","value":"35","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"103","spread":null},{"groupId":"OG001","value":"45","spread":null},{"groupId":"OG002","value":"148","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"84","spread":null},{"groupId":"OG001","value":"40","spread":null},{"groupId":"OG002","value":"65","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"203","spread":null},{"groupId":"OG001","value":"88","spread":null},{"groupId":"OG002","value":"248","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG002","value":"18","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"46","spread":null},{"groupId":"OG001","value":"14","spread":null},{"groupId":"OG002","value":"65","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"151","spread":null},{"groupId":"OG001","value":"74","spread":null},{"groupId":"OG002","value":"159","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"202","spread":null},{"groupId":"OG001","value":"88","spread":null},{"groupId":"OG002","value":"242","spread":null}]}]}]},{"type":"SECONDARY","title":"Alternative Booster Responses to Anti-PT, Anti-FHA and Anti-PRN Antigens","description":"Alternative Booster response to PT, FHA and PRN antigens is defined as: - For subjects with pre-booster antibody concentration below the assay cut off: antibody concentrations at least four times the assay cut off one month after vaccination, and - For subjects with pre-booster antibody concentration ≥ assay cut off and \\< 60 IU/mL: antibody concentration increase of at least 30 IU/mL from the pre-booster antibody concentration, one month after vaccination. - For subjects with pre-booster antibody concentration ≥ 60 IU/mL : at least 1.5 fold increase of antibody concentration from the pre-booster antibody concentration, one month after vaccination. S- = seronegative subjects (antibody concentration below assay cut off for anti-PT, anti-FHA, anti-PRN) S+ = seropositive subjects (antibody concentration below assay cut off for anti-PT, anti-FHA, anti-PRN) Total = subjects either seropositive or seronegative","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"171","spread":null},{"groupId":"OG001","value":"91","spread":null},{"groupId":"OG002","value":"241","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"82","spread":null},{"groupId":"OG001","value":"27","spread":null},{"groupId":"OG002","value":"64","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"253","spread":null},{"groupId":"OG001","value":"119","spread":null},{"groupId":"OG002","value":"310","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"31","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"115","spread":null},{"groupId":"OG001","value":"52","spread":null},{"groupId":"OG002","value":"185","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"111","spread":null},{"groupId":"OG001","value":"53","spread":null},{"groupId":"OG002","value":"62","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"230","spread":null},{"groupId":"OG001","value":"106","spread":null},{"groupId":"OG002","value":"278","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"34","spread":null},{"groupId":"OG001","value":"10","spread":null},{"groupId":"OG002","value":"101","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"169","spread":null},{"groupId":"OG001","value":"83","spread":null},{"groupId":"OG002","value":"166","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"3","spread":null},{"groupId":"OG002","value":"10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"210","spread":null},{"groupId":"OG001","value":"96","spread":null},{"groupId":"OG002","value":"277","spread":null}]}]}]},{"type":"SECONDARY","title":"Seroprotection Status for Anti-D Antibody Concentration","description":"Seroprotection status for anti-D antibody concentration \\< 0.1 IU/mL were tested for neutralizing antibodies using a VERO-cell neutralization assay. Seroprotection rate is defined as the percentage of subjects with antibody concentrations greater than or equal (≥) the seroprotection cut-off value defined for that antibody.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.3","spread":null},{"groupId":"OG001","value":"40.0","spread":null},{"groupId":"OG002","value":"27.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null},{"groupId":"OG002","value":"14.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Year 9","description":"Solicited local symptoms assessed were pain, redness and swelling. Any was defined as any solicited local symptom reported irrespective of intensity. Grade 3 pain was defined as significant pain at rest that prevented normal everyday activities. Grade 3 redness and swelling was greater than 50 millimeters (mm)","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"180","spread":null},{"groupId":"OG001","value":"84","spread":null},{"groupId":"OG002","value":"132","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"74","spread":null},{"groupId":"OG001","value":"32","spread":null},{"groupId":"OG002","value":"53","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"57","spread":null},{"groupId":"OG001","value":"26","spread":null},{"groupId":"OG002","value":"41","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"2","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms - Year 9","description":"The solicited general symptoms assessed were Fatigue, Gastrointestinal symptoms (including nausea, vomiting, diarrhea and abdominal pain), Headache and Fever \\[defined as temperature of ≥100.4 degrees Fahrenheit (F) by any route\\]. Any = Occurrence of any general symptom regardless of its intensity grade or relationship to vaccination; Grade 3 Symptom = Symptom that prevented normal activity; Grade 3 Fever \\> 104.0 degrees F.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"71","spread":null},{"groupId":"OG001","value":"23","spread":null},{"groupId":"OG002","value":"51","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"27","spread":null},{"groupId":"OG001","value":"4","spread":null},{"groupId":"OG002","value":"29","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"52","spread":null},{"groupId":"OG001","value":"25","spread":null},{"groupId":"OG002","value":"53","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Any Large Injection Site Reaction - Year 9","description":"Large injection site reaction = a swelling with a diameter \\> 100 mm, noticeable diffuse swelling or noticeable increase in limb circumference.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Any Unsolicited Adverse Events (AEs) - Year 9","description":"An unsolicited AE covers any untoward medical oc-currence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"42","spread":null},{"groupId":"OG001","value":"23","spread":null},{"groupId":"OG002","value":"37","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Serious Adverse Events (SAEs) - Year 9","description":"SAEs assessed include medical occurrences that result in death, are life-threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":309},"commonTop":["Pain","Erythema","Fatigue","Headache","Swelling"]}}}